Prime Medicine (PRME) Return on Equity (2022 - 2026)

Prime Medicine (PRME) has 5 years of Return on Equity data on file, last reported at 0.02% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity changed 0.0% year-over-year to 0.02%; the trailing twelve-month figure through Mar 2026 stood at 0.02% (changed 0.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.02%, down from 0.01% in the prior quarter.
• Across five years, Return on Equity topped out at 0.01% in Q2 2022 and bottomed at 0.03% in Q4 2022.
• The 5-year median for Return on Equity is 0.01% (2024), against an average of 0.01%.
• Peak annual rise in Return on Equity reached 1 bps in 2023, while the deepest fall reached 1 bps in 2023.
• A 5-year view of Return on Equity shows it stood at 0.03% in 2022, then jumped by 54 bps to 0.01% in 2023, then climbed by 6 bps to 0.01% in 2024, then dropped by 27 bps to 0.01% in 2025, then sank by 42 bps to 0.02% in 2026.
• The last three Return on Equity figures came in at 0.02% (Q1 2026), 0.01% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.

Peer Comparison